Figure 2.

MSL subtype TNBC cells are resistant to either gefitinib or SU11274 in spite of high expression of EGFR and MET. (A) Cell lysates from exponentially growing cells were subjected to western blot analysis with indicated antibodies. β-actin was used as a loading control. (B and C) Cells were incubated with increasing concentrations of gefitinib (B) or SU11274 (C) for ≤72 h and the viable cells were determined by MTT cell viability assay. Data are presented as mean ± SEM from three independent experiments performed in triplicate.